Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTap-IPV vs DAPTACEL + IPOL as 5th Dose Booster
NCT01346293Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2011
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of pertactin in diphtheria, Tetanus, pertussis, poliomyelitis, sponsored by Sanofi. Started Apr 2011; status: completed.
02
Drugs
pertactin
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT01346293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01346293.